News
Why Teva Pharmaceutical Industries Stock Fell for a Second Straight Day
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down 9.8% as 1:15 p.m. EDT after dropping by an even greater amount yesterday following disappointing second-quarter results and lowered
Why Spectrum Pharmaceuticals Stock Is Bolting Higher Today
As of 1:28 p.m. EDT, shares of Spectrum Pharmaceuticals (NASDAQ: SPPI), a biotech developing treatments for various blood disorders and cancers, are up by over 21% on elevated volume. The drugmaker's
BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter
BioMarin Pharmaceutical (NASDAQ: BMRN) turned in a second-quarter report on Wednesday that showed it continuing to grow sales of its current drugs, getting new drugs approved, and producing promising
Here's Why PDL BioPharma Inc. Is Soaring Today
Shares of PDL BioPharma Inc. (NASDAQ: PDLI), a biopharma royalty company, are surging Friday in response to the positive second-quarter earnings report it issued after the bell Thursday. A quarterly
Why AstraZeneca plc Stock Broke Down in July
Big Pharma stocks don't usually drop by double-digits over the course of a month, but that's exactly what happened to British pharma giant AstraZeneca plc (NYSE: AZN) in July. Due to the late-stage
This Marijuana Stock Could Be 1 Clinical Trial Away From a $1 Billion Valuation
Few industries in the U.S. are growing at a quicker pace than legal marijuana. According to a fairly recent report from Marijuana Business Daily, entitled "Marijuana Business Factbook 2017," legal pot
Why Sarepta Therapeutics Stock Gained 10.7% in July
Sarepta Therapeutics (NASDAQ: SRPT), a biotech developing novel treatments for rare disorders, saw its shares rise by a healthy 10.7% last month, according to S&P Global Market Intelligence. The
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important
It's been a pretty good year for Juno Therapeutics (NASDAQ: JUNO) so far. The clinical-stage biotech's share price is up more than 50% year-to-date. Its financial position in the first quarter looked
Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter
Momenta Pharmaceuticals (NASDAQ: MNTA) continued to tread water in the second quarter, waiting for approval by the U.S. Food and Drug Administration of its copycat of the three-times weekly version of
3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
Any way you look at, Exelixis (NASDAQ: EXEL) just reported an impressive second-quarter performance. The biotech posted its second quarter of profitability, with earnings topping Wall Street
Here's Why Curis, Inc. Dropped as Much as 14.5% This Morning
Shares of clinical-stage biopharma Curis, Inc. (NASDAQ: CRIS) dropped over 14% this morning after the company released second-quarter 2017 financial results and provided an update on a phase 2 trial
Here's Why Dynavax Technologies Corporation Stock Shot Up 64.2% in July
In July, a 12-to-1 Food and Drug Administration advisory committee vote in favor of Dynavax Technologies Corporation's (NASDAQ: DVAX) experimental hepatitis B vaccine allayed previous concerns that
Genomic Health, Inc.: Still Waiting for Reimbursement
Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net
3 Reasons the Best Is Yet to Come for Celgene
Celgene Corp.'s (NASDAQ: CELG) second-quarter revenue and sales came in nearly 50% higher than they were two short years ago, yet the company doesn't appear to be anywhere near peaking. A flurry of
Why Corcept Therapeutics Incorporated Stock Surged Higher Today
Shares of the rare-disease specialist Corcept Therapeutics Incorporated (NASDAQ: CORT) rose by 8.78% on heavy volume today, due to a stronger-than-expected second-quarter earnings report
3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment
Novocure (NASDAQ: NVCR) is the company behind TTFields, a revolutionary new and nontoxic treatment for glioblastoma that uses low-intensity, alternating electrical fields to impede cancerous cell
Here's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
Shares of ImmunoGen, Inc. (NASDAQ: IMGN), an oncology-focused biotech, dipped 16.5% lower in July according to data from S&P Global Market Intelligence. A fairly benign earnings report near the end of
3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic
The opioid epidemic is a huge and tragic problem, and the market is starved for solutions. Flexion Therapeutics (NASDAQ: FLXN) is one company that's working on filling that gap and is close to
Here's Why Spark Therapeutics Inc. Is Soaring Today
After reporting second-quarter results that contained upbeat clinical news, Spark Therapeutics (NASDAQ: ONCE), a clinical-stage company focused on gene therapy, rose 18% as of 12:30 p.m. EDT on
Here's Why Amarin Corporation plc Is on the Rise Today
Shares of Amarin Corporation plc (NASDAQ: AMRN), a cardiovascular health-focused biotech, popped 12.9% higher this morning after reporting second-quarter earnings. Investors cheered the
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus
3 Biotech Stocks With Big News Coming
Clinical trial data and FDA decisions can cause biotech stocks to pop or drop, and that makes it critical for biotech investors to keep a close eye on Flexion Therapeutics (NASDAQ: FLXN), Keryx